Nano-X Imaging Ltd. (NASDAQ: NNOX) (“Nanox”), a medical imaging technology company, announced two strategic developments that expand the commercial reach and technical flexibility of its AI-driven imaging solutions. The company entered an exclusive three-year reseller agreement with Vertec Scientific to distribute HealthOST in the United Kingdom, and separately optimized its imaging AI framework for Intel Core Ultra processors using OpenVINO, allowing AI inference to run locally on hospital hardware.
The UK agreement includes minimum annual license commitments, establishing a dedicated channel for HealthOST, an AI-powered software that provides qualitative and quantitative analysis of spinal CT images to help clinicians evaluate spinal musculoskeletal disease, including osteoporosis. This move gives Nanox a direct commercial pathway in a key European market and aims to drive adoption of its AI tools among UK healthcare providers.
In parallel, Nanox.AI optimized its framework for Intel Core Ultra processors with OpenVINO, demonstrating the potential to perform AI inference locally on hospital hardware. This could reduce reliance on cloud connectivity, offering healthcare providers more flexible deployment options and potentially lowering latency and data transfer concerns. Together, these developments support Nanox.AI’s strategy of extracting additional clinical value from already performed scans while expanding commercial reach.
For investors and industry observers, the announcements signal progress in Nanox’s efforts to monetize its AI portfolio and adapt to different healthcare IT environments. The UK reseller deal provides a recurring revenue stream through license commitments, while the Intel optimization could make Nanox’s solutions more attractive to hospitals with limited or unreliable internet access, or those with data sovereignty requirements. The ability to run AI locally may also appeal to institutions seeking to keep patient data on-premises.
Nanox’s broader ecosystem includes Nanox.ARC, a cost-effective 3D multi-source digital tomosynthesis imaging system; Nanox.AI, a suite of AI-based algorithms that augment routine CT interpretation; Nanox.CLOUD, a cloud-based platform for secure data management and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts; and Nanox Health IT, which delivers RIS, PACS, AI, dictation, and secure infrastructure solutions. For more information, visit www.Nanox.vision. The latest news and updates relating to NNOX are available in the company’s newsroom at https://ibn.fm/NNOX.
The full article can be viewed at https://ibn.fm/eBRgx. This news was originally distributed by BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire, editorial syndication to 5,000+ outlets, and social media distribution. Additional corporate communications solutions are also available. Terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
